Despite radical surgery and multi-agent chemotherapy, less than one third of patients with recurrent or metastatic osteosarcoma (OS) survive. The limited efficacy of current therapeutic approaches to target tumor-initiating cells (TICs) may explain this dismal outcome. The purpose of this study was to assess the impact of modified T cells expressing a human epidermal growth factor receptor (HER2)-specific chimeric antigen receptor in the OS TIC compartment of human established cell lines. Using the sarcosphere formation assay, we found that OS TICs were resistant to increasing methotrexate concentrations. In contrast, HER2-specific T cells decreased markedly sarcosphere formation capacity and the ability to generate bone tumors in immunodeficient mice after orthotopic transplantation. In vivo, administration of HER2-specific T cells significantly reduced TICs in bulky tumors as judged by decreased sarcosphere forming efficiency in OS cells isolated from explanted tumors. We demonstrate that HER2-specific T cells target drug resistant TICs in established OS cell lines, suggesting that incorporating immunotherapy into current treatment strategies for OS has the potential to improve outcomes.
Introduction
Osteosarcoma (OS) is the most common malignant bone tumor of childhood. Radical surgery and adjuvant multi-agent chemotherapy have been the mainstream treatment for the last 30 years, and current studies report a 5 year disease-free survival of 60-70%. 1 Outcomes for patients with metastatic or recurrent disease, however, remain poor despite modifications to available therapeutic regimens.
The failure of current treatments may result from lack of targeting of tumor-initiating cells (TICs) in OS. 2 TICs, also known as cancer stem cells, constitute a fraction of tumor cells characterized by both their self-renewal capacity and their increased tumorigenicity. 3 TICs have been identified in OS by the expression of certain surface markers or as a 'side population' through the exclusion of the vital dye Hoechst 33342. [4] [5] [6] In addition, OS TICs can be grown in culture as sphere-like structures (sarcospheres) under serum starvation, 7 a property that allows functional testing of different anti-neoplastic agents against this tumor cell compartment. Furthermore, OS TICs have been reported to be resistant to chemotherapy. 8, 9 The human epidermal growth factor receptor (HER2) is expressed by up to 60% of primary OS and correlates with poor prognosis. 10, 11 Previously, we have shown that genetically modified T cells expressing a HER2-specific chimeric antigen receptor exerted potent antitumor activity against OS cells in vitro. Furthermore, HER2-specific T cells induced regression of established OS xenografts in mice, increasing survival in treated animals. 12 T cells exert their antitumor activities via perforin/ granzyme-based cytotoxicity, which in addition to killing the bulk of tumor cells may also affect the OS TIC compartment. The purpose of this study was to asses the impact of HER2-specific T cells on the TIC subpopulation in established OS cell lines.
Materials and methods
Monolayer and sarcosphere toxicity assays Two established human OS cell lines (MNNG/HOS and 143B) were acquired from the American Type Culture Collection (Manassas, VA). To allow fluorescent-activated cell sorting (FACS), MNNG/HOS and 143B cells were transduced with a lentiviral-vector encoding the ZsGreen fluorescent reporter. 13 Zs Green-expressing tumor cells were grown in 100 mm 2 dishes in minimal essential medium (MEM) supplemented with 10% fetal bovine serum (complete media) until 80-90% confluency. Methotrexate (Genera Medix, Liberty Corner, NJ) was added to the media for 4 h at increasing concentrations (0.0001-1 mMl
À1
). Tumor cells were dissociated using trypsin 0.25% (Invitrogen, Carlsbad, CA) and single-cell suspensions were sorted by FACS utilizing the FACSAriaII (BD Biosciences, San Jose, CA). Viable MNNG/HOS and 143B cells were plated again in complete media. The OS cell repopulation capacity was assessed by determining tumor cell confluency 7 days after treatment. Results are expressed as percentage of untreated (control) cells.
OS TICs were grown as sarcospheres in non-adherent plates with growth factors in a serum-free medium as described previously. 7, 13, 14 To test the effect of methotrexate on OS TICs, single-cell suspensions of ZsGreenexpressing 143B and MNNG/HOS cells were exposed to methotrexate for 4 h at increasing concentrations (0.0001-1 mMl
) and cultured in 'sarcosphere medium'. Subsequently, sarcospheres were trypsinized and viable cells were sorted for the expression of ZsGreen. Single-cell suspensions were plated again in the same cell culture conditions. After 7 days, secondary sarcosphere images were taken using an inverted dissecting microscope and counted using Image Pro-Plus software (Bethesda, MD). Similarly, to test the effect of immunotherapy in OS TICs, ZsGreen-expressing 143B and MNNG/HOS cells were co-cultured for 48 h either with HER2-specific T cells or with non-specific T cells at 1:1, 1:5 and 1:10 effector to target ratios. The generation of HER2-specific and nonspecific T cells has been described elsewhere. 12 Tumor cells were sorted for the expression of ZsGreen, and re-plated in 'sarcosphere medium'. Sarcosphere forming capacity was calculated as the percentage of sarcospheres generated by 5000 cells plated in each well for all experimental groups, compared with the control group after 7 days of treatment.
Cytotoxicity assay
Cytotoxicity assays were conducted on methotrexateresistant OS TIC as described previously. 12, 15 Briefly, Zs Green-expressing 143B cells were culture on sarcosphereforming media with different methotrexate concentrations for 4 h. Viable OS cells were sorted for ZsGreen and 1 Â 10 6 target cells were labeled with 0.1 mCi (3.7 MBq) 51 Cr and mixed with decreasing number of effector cells to give E:T ratios of 40:1, 20:1 and 10:1. Target cells incubated in complete medium alone of in 1% Triton X-100 were used to determine spontaneous and maximum 51 Cr release, respectively. After 8 h, supernatants were collected and radioactivity was measured in a gamma counter (Perkin Elmer, Waltham, MA). The mean percentage of specific lysis of triplicate wells was calculated according to the following formula: (test releaseÀspontaneous release)/ (maximum releaseÀspontaneous release) Â 100.
Flow cytometry OS cell lines were analyzed with HER2 (Becton Dickinson, San Jose, CA) and CD133 antibodies (Miltenyi Biotec, Auburn, CA). In all cases, negative controls included isotype antibodies. For these experiments, we used a FACS Calibur instrument and CellQuest software (both form Becton Dickinson), analyzing 410 000 events.
Orthotopic xenograft model All animal procedures followed a protocol approved by Baylor College of Medicine Institutional Animal Care and Use Committee. Four to 5-week-old male non-obese diabetic/severe combined immunodeficiency (NOD/ SCID) mice were obtained from Jackson Laboratory (Bar Harbor, ME). Animals were anesthetized with isofluorane and maintained under sterile airflow conditions during the experiments. In preparation for tumor cell injection, ZsGreen-expressing 143B cells were cocultured with HER2-specific or non-specific T cells at 1:10 effector to target ratio under sarcosphere conditions for 4 h. Following FACS, 10 000 cells, suspended in 20 ml PBS/matrigel (1:1), were injected into the right tibia of NOD/SCID mice. Animals were monitored daily until 12 weeks after injection or when tumors reached 1 cm in diameter. The right tibia and both lungs were then dissected and removed for inspection using a fluorescent microscope under brightfield or green fluorescent protein (GFP) filter.
To monitor the tumor formation in vivo, 143B cells were transduced with a retroviral vector encoding an enhanced GFP firefly luciferase (eGFP.FFLuc) fusion gene. 16 A total of 20 000 eGFP.FFLUC-expressing 143B cells were injected into the right tibia of NOD/SCID mice. After 4 weeks, all animals developed bone tumors as judged by bioluminescence imaging and were treated with single-tail vein injection of 1 Â 10 6 HER2-specific and non-specific T cells. Animals were euthanized within 3-6 days after treatment. The soft tissue portion of bone tumors was minced and processed using 2 mg ml À1 collagenase A (Roche, Indianapolis, IN) with mechanical methods for FACS analysis. Tumor cells were sorted based on the expression of GFP. Single-cell suspensions were cultured under sarcosphere conditions. After 7days, we visualized the sarcospheres generated from orthotopic bone tumors and estimated sarcosphere forming efficiency (percentage of the total number of spheres per well divided by plated cells).
Results

OS TICs are resistant to methotrexate in vitro
Methotrexate kills OS cells and is a key component of modern chemotherapeutic treatment regimens of OS. 17 We evaluated the effect of increasing methotrexate concentrations on human OS cells cultured under two different conditions; as monolayers with serum-containing medium or as sarcospheres under serum starvation. After 4-h exposure to methotrexate, 450% of OS cells were killed in the monolayer culture system. By contrast, sarcospheres were methotrexate resistant, with little effect on their growth pattern in cultures with the drug. An effect was observed only with a 100-fold increase in concentration (Figure 1a) . Hence, OS cells with sarcosphere potential (TIC) are resistant to methotrexate in vitro.
HER2-specific T cells efficiently inhibit the growth of OS TICs in vitro
HER2 is expressed at low levels by human OS cell lines. 12, 18 We previously showed that HER2-specific T cells efficiently eliminate HER2-positive OS tumor cells. 12 To evaluate if HER2-specific T cells also targeted OS TICs, we first determined the content of HER2 in OS TICs, as characterized by the expression of CD133. 5 OS TICs were uniformly HER2-positive, and expressed HER2 at higher levels than CD133-negative bulk OS cells (Figure 1b, left) . To determine whether OS TICs are killed by HER2-specific T cells in vitro, we plated ZsGreen-expressing 143B and MNNG/HOS cells under sarcosphere-forming conditions in conjunction with HER2-specific or non-specific T cells. Although HER2-specific T cells significantly reduced the number of sarcospheres in comparison with untreated controls, non-specific T cells did not (Figure 1b , right, and Figure 1c ). Furthermore, we demonstrated in a standard 51 Cr release assay that HER2-specific T cells induced lysis of OS TIC that survived exposure to various concentrations of methotrexate (Supplementary Figure 1) . Hence in contrast to methotrexate, HER2-specific T cells effectively eliminated OS TICs. Targeting tumor-initiating cells in osteosarcoma N Rainusso et al
HER2-specific T cells decrease the tumorigenicity of OS cells in an orthotopic mouse model
The functional definition of TICs requires an increased capacity to generate tumors in immunodeficient mice. 19 ZsGreen-expressing 143B cells were cultured with HER2-specific T cells or non-specific T cells for 4 h before injection of 10 000 OS cells into the proximal tibia of NOD/SCID mice. To avoid killing of all OS cells and to evaluate these effects in OS TICs, tumor cells were sorted and injected without T cells. Viable 143B cells formed bone tumors in 81% of mice in the control and non-specific T-cell groups. In contrast, only 25% of mice receiving viable 143B cells pre-treated with HER2-specific T cells bore bone tumors (Figure 2a) . Moreover, 143B cells pre-treated with HER2-specific T cells induced tumors, which were smaller and appeared to be associated with a decreased number of lung metastases (Figures 2a  and b) .
Having established that HER2-specific T cells target OS TICs as judged by their ability to reduce the tumorigenicity of OS cells, we determined whether HER2-specific T cells could target OS TICs in vivo. We intravenously injected NOD/SCID mice bearing large, established orthotopic bone tumors with a subtherapeutic dose (1 Â 10 6 cells) of HER2-specific or non-specific T cells. Mice were euthanized within 3-6 days after receiving T-cell injections. We did not observe a difference in tumor size among the experimental groups (Figure 2c) . However, tumor size may not adequately reflect the therapeutic effect in TICs. 20, 21 To test the self-renewal potential of the treated tumors, we performed sarcosphere assays on the freshly digested tumors. A significant decrease in the sarcosphere forming efficiency from tumors treated with HER2-specific T cells, in comparison with the control and non-specific T cells, was observed 3 and 6 days post-treatment (Figure 2d) . Hence, HER2-specific T cells target OS TICs, as judged by their ability to reduce OS tumorigenicity after pretreatment in vitro as well as sarcosphere forming efficiency after in vivo administration.
Discussion
There has been no improvement in the outcome of OS for 30 years, and one third of patients still succumb to their disease. Therefore, there is a critical need for new therapeutic approaches in the clinical management of OS, and selectively targeting TICs in combination with conventional therapies may be one means of accomplishing this aim. 22 We have shown now HER2-directed immunotherapy can target the TICs of OS.
OS TICs can be characterized in established cell lines and primary bone tumors by multiple means. [4] [5] [6] [7] 13 Their enhanced capacity to form sarcospheres is a surrogate of their self-renewal property regardless of the method used to characterize and isolate this cell subpopulation from Targeting tumor-initiating cells in osteosarcoma N Rainusso et al the tumor bulk. Sarcospheres have previously been shown to be resistant to doxorubicin, cisplatin and vincristine, 8, 9 and we now show they are also resistant to methotrexate. Previously, West et al. 23 showed that methotrexate had limited penetration in human OS spheroids, which might explain the tumor cell resistance to this agent. However, in our experiments we exposed single cells to methotrexate before sarcosphere formation, which should eliminate this confounding factor. Thus, OS TICs appear resistant to most of the agents used as current standard of care for OS.
Our group has shown that genetically modified T cells redirected against HER2 eliminates locoregional OS and metastatic tumors in xenograft transplants in mice. 12 The current study expands those results and demonstrates that HER2-specific T cells kill OS TICs, both in vitro and in vivo, in addition to HER2-positive non-TICs. Our in vitro and orthotopic transplants studies used identical number of OS cells in all experimental groups (control, HER2-specific and non-specific T cells), and tumor cells were labeled either with ZsGreen or with eGFP.FFLuc to allow FACS elimination of lymphocytes. The observed differences in sarcosphere forming efficiency or the ability to generate bone tumors are difficult to interpret if the stem-like cell compartment is not targeted. We observed a persisting albeit low level formation of sarcospheres and bone tumors even after treatment with HER2-specific T cells, which could be due to the persisting low level innate tumorigenic capacity of the non-TIC population or to incomplete eradication of OS TICs. In addition, we observed that HER2-specific T cells affect the OS TIC compartment in established bone tumors. Although tumor size was unchanged among the experimental groups, the self-renewal capacity of OS cells within tumors was impaired after treatment. These findings suggest that the combination of chemotherapy and immunotherapy would be necessary to eliminate the bulk of tumor cells and TICs. Our data also show that the number of lung metastases was less in the treatment group by HER2 specific-T cells. OS TICs have been found to express genes involved in the processes of cell migration and metastasis. 4, 13 Therefore, targeting this tumor cell compartment may impair the ability of OS cells to metastasize.
In summary, we demonstrate that HER2-specific T cells target drug resistant putative TICs in established OS cell lines, suggesting that immunotherapy may contribute to the elimination of residual disease in OS and thereby enhance long-term survival.
